Prostate Cancer: Home Saliva Test for High-Risk Patients
Genetic Saliva Test shows promise in Prostate Cancer Screening
Table of Contents
- Genetic Saliva Test shows promise in Prostate Cancer Screening
- Revolutionizing Prostate Cancer Screening: Yoru Questions answered
- Frequently Asked Questions
- 1. What is the latest breakthrough in prostate cancer screening?
- 2.How does this genetic saliva test work?
- 3.What are the limitations of current prostate cancer screening methods, like the PSA test?
- 4. What are the key findings from the “Barcode 1” study?
- 5. How does the genetic test compare to the PSA test in terms of accuracy?
- 6. What are the potential benefits of this new genetic test?
- 7. What is the “Transform Project”?
- 8. Can you share real-life examples of the test’s impact?
- 9. Who is Kristian Helin, and what’s his perspective on this test?
- 10. Where can I find more information about this study?
- Frequently Asked Questions
LONDON, England (2025-04-12) — A new genetic saliva test could revolutionize prostate cancer screening, offering a more precise method for identifying aggressive tumors, according to a study by researchers at the Institute of Cancer Research in London and the Royal marsden NHS Foundation Trust.The study, published in the new England Journal of Medicine, suggests the test can help avoid unneeded treatments and improve early detection.
Prostate cancer remains a notable health concern. In the United Kingdom, about 55,000 men are diagnosed annually, with over 12,000 deaths. France sees nearly 50,000 diagnoses and more than 8,100 deaths each year. Current screening methods, particularly the PSA test, frequently enough struggle to differentiate between aggressive and slow-growing tumors, leading to both false positives and missed diagnoses of risky cancers.
How the Genetic Test Works
The saliva test is designed for at-home use. Patients send a saliva sample to a lab for genetic analysis. Researchers then extract DNA to identify 130 specific genetic variations linked to an increased risk of prostate cancer. These variations, identified through large-scale studies involving hundreds of thousands of men, are statistically associated with the disease.
These markers are used to calculate a polygenic risk score (PRS) for each individual. A higher PRS indicates a greater risk of developing aggressive prostate cancer. The score is based on the cumulative effect of multiple small genetic factors, rather than a single mutated gene.
Barcode 1 Study Results
The Barcode 1 study involved 6,142 European men aged 55 to 69. Participants were recruited through their general practitioners. Researchers identified the 10% with the highest PRS scores and invited them for prostate MRIs followed by biopsies.
The study found that 40% of men in the high-risk group were diagnosed with prostate cancer, demonstrating the test’s ability to target individuals who would benefit most from further examination.
Addressing the Shortcomings of PSA Testing
The widely used PSA (Prostate Specific Antigen) blood test has limitations. While it measures a protein produced by the prostate, elevated levels can result from cancer or benign conditions like infection or benign hyperplasia. This leads to unnecessary MRIs, biopsies, and treatments, which can cause side effects such as erectile dysfunction, urinary incontinence, and anxiety.
furthermore, the PSA test often detects slow-growing tumors that pose no threat to a patient’s life.
Genetic Test Offers Improved Precision
The saliva-based genetic test offers greater precision. In the barcode 1 study, 55.1% of the 187 cancers identified using the PRS test were aggressive,compared to 35.5% of cancers detected via PSA in a previous study. The PRS test is more effective at identifying clinically significant cancers.
Notably, 66.8% of confirmed cancers were not visible on MRI, and 63.1% of diagnosed men had normal PSA levels. The genetic test fills the gaps in conventional screening, avoiding overdiagnosis while identifying at-risk individuals.
Potential for a Paradigm Shift
This advancement could transform prostate cancer screening. The PRS test’s ease of use, requiring only a saliva sample collected at home, facilitates large-scale implementation. Researchers estimate that it could detect up to 12,350 cancers annually in the United Kingdom and save the National Health Service (NHS) £500 million.
The test is the result of decades of research and is now part of the Transform project, a clinical trial funded by Prostate Cancer UK with £42 million. the trial will compare the saliva test’s performance against PSA and MRI, while also assessing its value for men with low genetic risk. An extended version of the test, called Prodict®, is also being studied.
Real-Life Impact: Two brothers’ Stories
The stories of dheeresh and Joël Turnbull illustrate the test’s potential impact. Dheeresh,71,participated in the Barcode 1 study after receiving a letter from his doctor. Despite having no symptoms, a normal PSA level, and no family history of prostate cancer, the PRS test revealed he was in the highest-risk group. Further tests confirmed aggressive, potentially deadly cancer.
His younger brother, Joël, decided to get tested as well, even though he did not meet the initial inclusion criteria. He, too, was diagnosed with aggressive prostate cancer.
“It is incredible to think that, thanks to this study, two lives were saved in my family,”
Dheeresh, as quoted in the Daily Mail
Their case highlights that the absence of symptoms or family history does not guarantee the absence of risk. Only a genetic profile-based test can identify these hidden risks.
Kristian Helin, director of the Institute of Cancer Research, emphasized the importance of early detection of clinically significant cancers to maximize the chances of prosperous treatment, reduce unnecessary interventions, and save lives. The PRS test offers a simple, rigorous, and efficient approach to achieving these goals.
source: Jana K.Mchog, et al., ”Assessment of a Polygenic Risk Score in Screening for prostate cancer”. N Engl J Med 2025; 392: 1406-1417
Revolutionizing Prostate Cancer Screening: Yoru Questions answered
Prostate cancer remains a significant concern for men worldwide. With new advancements in testing, there’s a growing interest in more accurate and accessible screening methods. This Q&A-style blog post delves into the promising field of genetic saliva tests for prostate cancer, answering your most pressing questions based on the latest research.
Frequently Asked Questions
1. What is the latest breakthrough in prostate cancer screening?
The latest breakthrough is a genetic saliva test that could revolutionize prostate cancer screening.
According to a study by researchers at the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust, the test identifies aggressive tumors with greater precision, perhaps avoiding unnecessary treatments and improving early detection.
2.How does this genetic saliva test work?
this at-home test involves collecting a saliva sample and sending it to a lab for genetic analysis. Researchers extract DNA to identify 130 specific genetic variations linked to an increased risk of prostate cancer. These variations, identified through large-scale studies, are statistically associated with the disease.
These markers are then used to calculate a polygenic risk score (PRS) for each individual.A higher PRS indicates a greater risk of developing aggressive prostate cancer. This score is based on the cumulative affect of multiple small genetic factors rather than a single mutated gene.
3.What are the limitations of current prostate cancer screening methods, like the PSA test?
The PSA (Prostate-Specific Antigen) blood test has limitations. While it measures a protein produced by the prostate, elevated levels don’t always indicate the presence of cancer. Elevated levels can also result from benign conditions, like infection or benign prostatic hyperplasia.
This can lead to:
- Unnecessary MRIs and biopsies
- Treatments which can have side effects, such as erectile dysfunction, urinary incontinence, and anxiety.
- Detecting slow-growing tumors that pose no threat.
4. What are the key findings from the “Barcode 1” study?
The “Barcode 1” study involved 6,142 European men. The study focused on men aged 55 to 69. Researchers identified the 10% with the highest PRS scores and invited them for prostate MRIs followed by biopsies. The study found that 40% of the high-risk group were diagnosed with prostate cancer.
5. How does the genetic test compare to the PSA test in terms of accuracy?
The saliva-based genetic test offers greater precision. In the Barcode 1 study, 55.1% of the 187 cancers identified using the PRS test were aggressive, compared to 35.5% of cancers detected via PSA in a previous study.The PRS test is more effective at identifying clinically significant cancers.
The genetic test fills the gaps in conventional screening, avoiding overdiagnosis while identifying at-risk individuals.Moreover:
- 66.8% of confirmed cancers were not visible on MRI
- 63.1% of diagnosed men had normal PSA levels.
This advantage of the genetic saliva test offers advantages over the PSA testing method.
6. What are the potential benefits of this new genetic test?
The saliva-based test could:
- Transform prostate cancer screening
- detect up to 12,350 cancers annually in the United Kingdom.
- Save the National Health Service (NHS) £500 million
The test’s ease of use, requiring only a saliva sample collected at home, facilitates large-scale implementation.
7. What is the “Transform Project”?
The saliva test is part of the transform project, a clinical trial funded by Prostate Cancer UK with £42 million. The trial will compare the saliva test’s performance against PSA and MRI, while also assessing its value for men with low genetic risk. This trial is the result of decades of research and is the next stage of this vital work.
An extended version of the test, called Prodict®, is also being studied.
Yes, the stories of Dheeresh and Joël Turnbull highlight the impact.Dheeresh, despite having no symptoms or family history of prostate cancer, was identified in the highest-risk group by the PRS test and diagnosed with aggressive cancer. His brother Joël also tested positive and was diagnosed with the disease.
“It is incredible to think that, thanks to this study, two lives were saved in my family,”
Dheeresh, as quoted in the Daily Mail
Their case highlights that the absence of symptoms or family history does not guarantee the absence of risk. Only a genetic profile-based test can identify these hidden risks.
9. Who is Kristian Helin, and what’s his perspective on this test?
Kristian Helin is the director of the Institute of Cancer Research. He emphasizes the importance of early detection of clinically significant cancers to maximize chances of successful treatment, reduce unnecessary interventions, and save lives. He highlights that the PRS test offers a simple, rigorous, and efficient approach to achieving these goals.
10. Where can I find more information about this study?
The primary source for this information is the study published in the New England Journal of Medicine in 2025 by Jana K. Mchog, et al., titled “Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.”
source: Jana K.mchog, et al.,”Assessment of a Polygenic Risk Score in Screening for prostate cancer”. N Engl J Med 2025; 392: 1406-1417